AFREZZA® REMS

FDA Required REMS Safety Information

- Risk of acute bronchospasm in patients with chronic lung disease
  - Acute Bronchospasm has been observed in patients with asthma and COPD using AFREZZA

- Contraindicated in patients with chronic lung disease such as asthma or COPD

- Need to evaluate all patients for lung disease before starting AFREZZA
  Before initiating AFREZZA, perform
  - a detailed medical history
  - physical examination, and
  - spirometry (FEV1)

Important Safety Notice
The FDA has required Sanofi US to distribute this safety notice to your organization as part of the AFREZZA REMS (Risk Evaluation and Mitigation Strategy) program. We request that you inform your members about the following serious risks of AFREZZA:

- Risk of Acute Bronchospasm in Patients with Chronic Lung Disease. Prescribers should counsel their patients to inform them if they have a history of lung disease. AFREZZA should not be used in patients with chronic lung disease

- Appropriate Patient Selection. AFREZZA is contraindicated in patients with chronic lung disease such as asthma or chronic obstructive pulmonary disease (COPD)

- Patient Evaluation Before Initiating Therapy. Before initiating, prescribers must perform a detailed medical history, physical examination, and spirometry (FEV1) in all patients, to identify potential underlying lung disease

A non-promotional factsheet, reviewed by the FDA, with more detailed safety information on these risks, and a link to the Prescribing Information including the BOXED WARNING are available at www.AfrezzaREMS.com.
Indication: AFREZZA® (insulin human) Inhalation Powder is a rapid acting inhaled insulin of action indicated to improve glycemic control in adult patients with diabetes mellitus.

**Important limitations of use:**
- Not a substitute for long-acting insulin. In patients with type 1 diabetes, must use with a long-acting insulin
- Not recommended for the treatment of diabetic ketoacidosis
- Not recommended in patients who smoke or have recently stopped smoking

This letter does not contain the complete safety profile for AFREZZA. Please see the Prescribing Information and Medication Guide, enclosed.

Signature,

[Signature]

Charles Hugh-Jones, M.D.
Vice President and Chief Medical Officer, North America Pharmaceuticals
Sanofi US